Literature DB >> 6512269

Mast cell degranulation in the evolution of acute eruptive guttate psoriasis vulgaris.

I Brody.   

Abstract

Clinically normal psoriatic skin (CNPS) and psoriatic lesions (PLs) were studied for mast cell degranulation (MCD) in patients with acute eruptive guttate psoriasis vulgaris (AEGP) following penicillin-treated acute streptococcal throat infection. The clinically manifest duration of psoriasis at the time of the biopsies was 2, 5, 10, 14, or 21 days. Two types of MCD were distinguished. Type I was characteristic for those portions of the CNPS in which vascular and epidermal changes were detected, while the PLs showed both Type I and Type II MCD. In Type I MCD the extruded granules (MCGs) in the immediate vicinity of the mast cells appeared as intact bodies encased in a distinctly trilaminar membrane. Around subepidermal and subpapillary blood vessels, in stratum papillare without proximity of blood vessels, beneath the epidermal-dermal junction, in lamina lucida, and in intercellular space of strata basale and spinosum the MCGs appeared partly as intact structures and partly in more or less disintegrated form. In Type II MCD the MCGs were extruded without perigranular membranes. The data here presented showed that MCD is an early and constant feature in the evolution of AEGP.

Entities:  

Mesh:

Year:  1984        PMID: 6512269     DOI: 10.1111/1523-1747.ep12260955

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  17 in total

Review 1.  Future modalities.

Authors:  M W Greaves
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

Review 2.  Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis.

Authors:  J T Elder
Journal:  Genes Immun       Date:  2009-03-05       Impact factor: 2.676

3.  Quantitative analysis of contact sites between mast cells and sensory nerves in cutaneous psoriasis and lichen planus based on a histochemical double staining technique.

Authors:  A Naukkarinen; I T Harvima; M L Aalto; R J Harvima; M Horsmanheimo
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

4.  Mast cells in the initial stages of psoriasis.

Authors:  B Toruniowa; S Jabłońska
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

5.  Mast cells and macrophages in early relapsing psoriasis.

Authors:  C Schubert; E Christophers
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

6.  Pathogenic function of IL-1 beta in psoriasiform skin lesions of flaky skin (fsn/fsn) mice.

Authors:  M Schön; C Behmenburg; D Denzer; M P Schön
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

7.  Mast cell density in psoriatic skin. The effect of PUVA and corticosteroid therapy.

Authors:  S Töyry; J Fräki; R Tammi
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

8.  Mast cell tryptase and chymase in developing and mature psoriatic lesions.

Authors:  I T Harvima; A Naukkarinen; K Paukkonen; R J Harvima; M L Aalto; L B Schwartz; M Horsmanheimo
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

Review 9.  Mast cell proteinases and cytokines in skin inflammation.

Authors:  I T Harvima; L Horsmanheimo; A Naukkarinen; M Horsmanheimo
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

10.  Experimentally induced psoriatic lesion associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing IL-33 and IL-6 receptor.

Authors:  M-M Suttle; G Nilsson; E Snellman; I T Harvima
Journal:  Clin Exp Immunol       Date:  2012-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.